G-Cin Tablet contains Gemifloxacin 320 mg, a fluoroquinolone antibiotic indicated for the treatment of various bacterial infections, including community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Gemifloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination, thereby preventing bacterial cell proliferation. G-Cin is effective against a broad spectrum of gram-positive and gram-negative pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The recommended dosage should be adhered to as prescribed by a healthcare professional to ensure optimal therapeutic outcomes and minimize the development of resistance. G-Cin is contraindicated in patients with known hypersensitivity to gemifloxacin or other quinolones. Caution is advised in patients with a history of tendon disorders related to quinolone use, as well as those with central nervous system disorders or cardiac arrhythmias. Common adverse effects may include gastrointestinal disturbances, headache, and rash. Patients should be advised to avoid excessive exposure to sunlight due to potential photosensitivity reactions. G-Cin should be used with caution during pregnancy and lactation, and its use in pediatric populations should be based on a thorough risk-benefit assessment.